Caroline C Farrington
Overview
Explore the profile of Caroline C Farrington including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
326
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jayappa K, Tran B, Gordon V, Morris C, Saha S, Farrington C, et al.
J Clin Invest
. 2023 May;
133(13).
PMID: 37166997
Targeted therapies such as venetoclax (VEN) (Bcl-2 inhibitor) have revolutionized the treatment of chronic lymphocytic leukemia (CLL). We previously reported that persister CLL cells in treated patients overexpress multiple antiapoptotic...
2.
Peris I, Romero-Murillo S, Martinez-Balsalobre E, Farrington C, Arriazu E, Marcotegui N, et al.
Blood
. 2022 Dec;
141(9):1047-1059.
PMID: 36455198
Venetoclax combination therapies are becoming the standard of care in acute myeloid leukemia (AML). However, the therapeutic benefit of these drugs in older/unfit patients is limited to only a few...
3.
Farrington C, Yuan E, Mazhar S, Izadmehr S, Hurst L, Allen-Petersen B, et al.
J Biol Chem
. 2019 Dec;
295(3):757-770.
PMID: 31822503
The tumor suppressor protein phosphatase 2A (PP2A) is a serine/threonine phosphatase whose activity is inhibited in most human cancers. One of the best-characterized PP2A substrates is MYC proto-oncogene basic helix-loop-helix...
4.
Farrington C, Narla G
Cancer Res
. 2019 Apr;
79(8):1756-1757.
PMID: 30987978
A hallmark of metastasis is the ability of cancer cells to undergo the epithelial-to-mesenchymal transition to invade and disseminate to distal sites. More recently, the case has been made that...
5.
Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky D, Zaware N, et al.
J Clin Invest
. 2017 May;
127(6):2081-2090.
PMID: 28504649
Targeted cancer therapies, which act on specific cancer-associated molecular targets, are predominantly inhibitors of oncogenic kinases. While these drugs have achieved some clinical success, the inactivation of kinase signaling via...
6.
Kastrinsky D, Sangodkar J, Zaware N, McClinch K, Farrington C, Giannini H, et al.
Bioorg Med Chem
. 2017 Mar;
23(23):7487.
PMID: 28290285
No abstract available.
7.
Sangodkar J, Farrington C, McClinch K, Galsky M, Kastrinsky D, Narla G
FEBS J
. 2015 Oct;
283(6):1004-24.
PMID: 26507691
Protein phosphatase 2A (PP2A) is a serine/threonine phosphatase involved in the regulation of many cellular processes. A confirmed tumor suppressor protein, PP2A is genetically altered or functionally inactivated in many...